Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II AZD4573 Monotherapy or Combination in Relapsed/Refractory PTCL or cHL
2021-002570-54Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zemirciclib in peripheral T-cell lymphoma (PTCL) and classical Hodgkin lymphoma (cHL), sponsored by AstraZeneca. Primary endpoint: Objective response rate (ORR). Started Nov 2021; status: completed.
02
Drugs
zemirciclib
03
Conditions
peripheral T-cell lymphoma (PTCL)classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2021-002570-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002570-54.